FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi
ReutersAug 28, 2025 6:11 PM
Aug 28 (Reuters) - The U.S. Food and Drug Administration said on Thursday it is recommending an additional, earlier magnetic resonance imaging monitoring prior to the third infusion for patients with Alzheimer's disease taking Biogen's BIIB.O drug Leqembi.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
[Crypto IPO] Trump Family Adds New Player: American Bitcoin Aims for Nasdaq Listing in September
American Bitcoin is set to make its debut on Nasdaq this September, marking another strategic expansion of the Trump family’s cryptocurrency ventures.TradingKey
12 hours ago
Four Key Disappointments in Nvidia’s Q2 FY2026 Earnings That Investors Can’t Ignore
TradingKey - AI chip leader Nvidia (NVDA) delivered revenue and profit growth above expectations in its second fiscal quarter ended July, with over 50% year-on-year growth, showcasing its strong momentum and leadership in artificial intelligence. However, capital markets viewed the report as “notTradingKey
13 hours ago
NVIDIA Q2 FY2026: Surfing the AI Surge with Blackwell, Steering Through China’s Export Challenges
TradingKey - NVIDIA Corporation (NASDAQ: NVDA) reported strong Q2 FY2026 results on August 27, 2025, after market close, driven by robust AI-powered demand and adoption of its next-generation Blackwell GPU platform. The company delivered significant revenue and profit beats overall, with...TradingKey
16 hours ago
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
CrowdStrike Stock Falls 9% After Disappointing Guidance: Time to Buy the Dip?
TradingKey - Cybersecurity is a booming industry, but even the best stocks can hit speed bumps. That’s exactly what happened to CrowdStrike Holdings Inc (NASDAQ: CRWD) after the company released its latest earnings report.TradingKey
Wed, Mar 5
